title: Managing residual risk in patients receiving statin therapy.
abstract: Until the results of several statin trials are available, it is recommended that the current indications and usage of ezetimibe be continued.
authors.forename: Ian R
authors.initials: IR
authors.lastname: Hamilton-Craig
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*
chemical_list: D008076:Cholesterol, HDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors